SPERO THERAPEUTICS INC (SPRO)       1.905  -0.03 (-1.8%)

1.905  -0.03 (-1.8%)

US84833T1034 - Common Stock


Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SPRO. SPRO was compared to 631 industry peers in the Biotechnology industry. SPRO has a bad profitability rating. Also its financial health evaluation is rather negative. SPRO is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating

1

SPRO has negative profitability rations, so we won't be analyzing them here.
SPRO has a Return On Assets of -158.86%. This is below the industry average of -44.83%. 91% of the industry peers outperform SPRO.

SPRO has a Profit Margin of -1162.35%. This is below the industry average of -464.10%.
SPRO has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of SPRO.
VS Industry

ROA (-158.86%) VS Industry: 9% outperformed.

-950.38
52.28

Profit Margin (-1162.35%) VS Industry: 32% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

1

With a price book ratio of 3.04, SPRO is valued correctly.
SPRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRO. No positive earnings are expected for the next year.
When comparing the price book ratio of SPRO to the average industry price book ratio of 1.69, SPRO is valued more expensive than its industry peers.
VS Industry

Price/Book (3.04) VS Industry: 29% outperformed.

131.89
0.10

Growth

Growth Rating

3

SPRO shows a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 121.81% yearly.
Based on estimates for the next 5 years, SPRO will show a small growth in Earnings Per Share. The EPS will grow by 5.13% on average per year.
SPRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.48%.

SPRO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -49.42%.
Based on estimates for the next 5 years, SPRO will show a very negative growth in Revenue. The Revenue will decrease by -22.91% on average per year.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -16.48% 14.06% 21.09% 7.67% 5.13%
Revenue121.81% 66.29% -49.42% -45.72% -47.51% -29.49% -22.91%

Health

Health Rating

2

SPRO has a Current Ratio of 3.26. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 3.26 indicates that SPRO has no problem at all paying its short term obligations.
The Debt to Equity ratio of SPRO is in line with the industry averages.
When comparing the Current Ratio of SPRO to the average industry Current Ratio of 6.16, SPRO is less able to pay its short term obligations than its industry peers.

When comparing the Quick Ratio of SPRO to the average industry Current Ratio of 6.05, SPRO is less able to pay its short term obligations than its industry peers.
SPRO has an Altman-Z score of -11.17. This is a bad value and indicates that SPRO is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of SPRO to the average industry Altman-Z score of -0.81, SPRO is less financially healthy than its industry peers. 85% of its industry peers have a better Altman-Z score.
SPRO has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of SPRO.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (3.26) VS Industry: 28% outperformed.

0.02
84.53

Current Ratio (3.26) VS Industry: 27% outperformed.

0.02
85.09

Altman-Z (-11.17) VS Industry: 15% outperformed.

-135.10
443.02

Dividend

Dividend Rating

0

No dividends for SPRO!.

SPRO Daily chart

SPERO THERAPEUTICS INC1.905

NASDAQ:SPRO (12/1/2022, 10:44:18 AM)-0.03 (-1.8%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-14 2022-11-14/amc Earnings (Next) 03-29 2023-03-29
Ins Owners 1.77% Inst Owners 38.4%
Market Cap 98.63M Analysts 80
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 11.19 P/B 3.04
EV/EBITDA -0.6
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -16.48% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 52.86%
EPS Next Y 14.06% EPS Next 2Y 21.09%
EPS Next 3Y 7.67% EPS Next 5Y 5.13%
Revenue growth 1Y -49.42% Revenue growth 3Y 66.29%
Revenue growth 5Y 121.81% Revenue growth Q2Q -34.53%
Revenue Next Year -45.72% Revenue Next 2Y -47.51%
Revenue Next 3Y -29.49% Revenue Next 5Y -22.91%
Health
Current Ratio 3.26 Quick Ratio 3.26
Altman-Z -11.17 F-Score 3
Debt/Equity 0 WACC 9.45%
ROIC/WACC N/A
Profitability
ROA -158.86% ROE N/A
ROICexgc N/A ROIC N/A
PM -1162.35% OM -952.41%
Asset Turnover 0.14

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA